badger, that is not unusual at all. Biogen outlicensed alpha interferon to Glaxo for very little in terms of royalties and didn't have its own product, beta interferon, for another 12 years.
I don't subscribe to the anti-Missling thinking here. I like him. He is smart and thoughtful and not greedy. He has made some bad decisions, this is true: he pulled a Daedalus on us and wasn't cautious enough with Rett and AD. But, Anavex is worth multiples of $3 even now and I think they can make good decisions now and turn this around.
Market Data 
Markets 
AI
